|
Designations:
|
Ramos (RA 1)
|
|
Depositors:
|
BC Giovanella
|
|
Isotype:
|
IgM; lambda light chain
|
|
Biosafety Level:
|
1
|
|
Shipped:
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
Growth Properties:
|
suspension
|
|
Organism:
|
Homo sapiens (human)
|
|
Morphology:
|
lymphoblast
|
|
Source:
|
Disease: Burkitt's lymphoma (American)
Cell Type: B lymphocyte;
|
|
Cellular Products:
|
immunoglobulin (surface and secreted) [1093] [22747]
|
|
Permits/Forms:
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
CRL-1596 RAMOS(RA 1)
|
|
Applications:
|
transfection host (Nucleofection technology from Lonza)
|
|
Receptors:
|
interleukin 4 (IL-4); low affinity IgE (CD23) [23468]
|
|
Tumorigenic:
|
Yes
|
|
Antigen expression:
|
CD23 + [23468]
|
|
DNA Profile (STR):
|
Amelogenin: X
CSF1PO: 10,11
D13S317: 13,14
D16S539: 10,13
D5S818: 7,12
D7S820: 11
THO1: 7,9.3
TPOX: 8,9
vWA: 15,16
|
|
Age:
|
3 years
|
|
Gender:
|
male
|
|
Ethnicity:
|
Caucasian
|
|
Comments:
|
The cells are negative for Epstein-Barr virus. [22747]
Both the parental line (ATCC CRL-1596)and the derivative cell line Ramos.2G6.4C10 (ATCC CRL-1923) have about 1500 IL-4 binding sites per cell. [23389]
The cells are reported to secrete IgM (lambda light chain). [1093]
|
|
Propagation:
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: heat-inactivated fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
|
|
Subculturing:
|
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml.
Maintain cell density between 2 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
|
|
Preservation:
|
culture medium 95%; DMSO, 5%
|
|
Related Products:
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
derivative:ATCC CRL-1923
|
|
References:
|
1093: Benjamin D, et al. Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type. J. Immunol. 129: 1336-1342, 1982. PubMed: 6286763
22747: Klein G, et al. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5: 319-334, 1975. PubMed: 181343
23389: Siegel JP, Mostowski HS. A bioassay for the measurement of human interleukin-4. J. Immunol. Methods 132: 287-295, 1990. PubMed: 1698879
23468: Rousset F, et al. Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFN-gamma. J. Immunol. 140: 2625-2632, 1988. PubMed: 2965726
26047: Nilsson K, et al. Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int. J. Cancer 19: 337-344, 1977. PubMed: 14896
32796: Bloom TJ, Beavo JA. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. USA 93: 14188-14192, 1996. PubMed: 8943082
|
